Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Embusartan SCHEMBL167147 | 1.00 | BDKRB1 (0.41) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5534640 | 0.95 | BDKRB1 (0.38) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5537210 | 0.95 | BDKRB1 (0.38) | BDKRB1AGTR1AGTR2 | |
| SCHEMBL5814612 | 0.91 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL8013981 | 0.91 | AGTR1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL8009750 | 0.91 | — | — | |
| SCHEMBL8007180 | 0.90 | — | — | |
| SCHEMBL8433566 | 0.90 | — | — | |
| SCHEMBL9412776 | 0.90 | BDKRB1 (0.43) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5537214 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117042763-A | Treatment of inflammatory diseases | 戴麦里克斯生物科学有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119816305-A | Use of MILVEXIAN in the treatment or prevention of ischemic stroke | 百时美施贵宝公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-114929694-B | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119278042-A | Chymase inhibitors for selective dissolution of thrombi in thrombotic or thromboembolic disorders | 索克普拉健康与人文科学公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115554300-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117042763-A | Treatment of inflammatory diseases | 戴麦里克斯生物科学有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116063580-A | Peptide analogues | 艾得佩索拉公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115583959-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115554300-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115554299-A | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-110719911-B | Diazabicyclo-substituted imidazopyrimidines and their use for the treatment of respiratory disorders | 拜耳股份公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115175681-A | Use of sGC activators for the treatment of ophthalmic diseases | 拜耳公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114981257-A | Substituted pyrazolopiperidinecarboxylic acids | 拜耳公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-108690016-B | Pyrazolopyridines and uses thereof | 广东东阳光药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114174326-A | Long-term stable adrenomedullin analogues and uses thereof | 拜耳公司 | 2022-03-11 | — | — | CN | disclosed |